Cancer - STAT

Something Ventured By Kate Sheridan

Triplet Therapeutics and three other startups got venture funding a year ago. Where are they now?

Biotech By Adam Feuerstein

The biotech scorecard for the first quarter: 17 stock-moving events to watch

Biotech By Adam Feuerstein

Agios sells cancer business to French drug maker for up to $2 billion, will now focus on inherited diseases

Don't Miss By Alissa Ambrose

STAT’s most memorable photos of 2020

Health By Elizabeth Cooney

Covid-19 surge could lead to another drop in patient visits, doctors fear — and more missed pediatric cancers

Health By Usha Lee McFarling

‘Why would we ever go back?’: Covid-driven shift to remote cancer clinical trials will likely outlast the pandemic

Biotech By Matthew Herper

With new data and a storied history, Eli Lilly’s blood cancer pill is looking stronger

STAT China By Jonathan Chan

Legend Biotech believes it is not a target of Chinese investigation, CEO says

Biotech By Eric Boodman

‘How are we going to get on that plane?’: The transatlantic race to deliver CAR-T cancer therapy during the pandemic

Health By Meghana Keshavan

Study offers new clues for treating brain cancer in children

Heavyweights By Eric Boodman

As a kid, his factory work paid for his dad’s cancer care. As an oncologist, his research offers more than survival

Breast Cancer Cell NCI National Cancer Institute

First Opinion By Linda S. Birnbaum and Margaret L. Kripke

The National Cancer Institute needs to publish information about chemical exposure and cancer risk

In the Lab By Elizabeth Cooney

Cancer vaccine cocktail boosts immune response after melanoma surgery, research shows

First Opinion By Ravi Parikh, Christopher Manz, and Mitesh Patel

A nudge helps doctors bring up end-of-life issues with their dying cancer patients

Health By Priyanka Runwal

Cancer clinical trial enrollment has plummeted. Will patients come back amid Covid-19?

Paper cup pills nonadherent noncompliant

First Opinion By Jessica Stuart

I was a ‘nonadherent’ patient. That’s made me a more empathetic doctor

Health By Priyanka Runwal

After a breast cancer diagnosis, many Black women face barriers that delay their care

In the Lab By Elizabeth Cooney

Training the innate immune system to thwart cancer could open door to a new therapy

Health Tech By Casey Ross

Google and the Mayo Clinic to use AI to better target radiation therapy

Health By Nicholas St. Fleur

Colorectal cancer screening should start five years earlier — at 45 — expert panel says

Biotech By Kate Sheridan

Exact Sciences acquires liquid biopsy company Thrive for $2.15 billion

Biotech By Adam Feuerstein

Mirati study results set new response bar for KRAS-blocking lung cancer drugs

Pharma By Rebecca Ritzel

FDA pushes drug companies to include younger people in breast cancer drug trials

chemotherapy patients community-based cancer care

First Opinion By Zachary A.K. Frosch, Lawrence N. Shulman, and Justin E. Bekelman

3 ways to counter Covid-19’s threat to community-based cancer care

Biotech By Adam Feuerstein

Most Read

How nanotechnology helps mRNA Covid-19 vaccines work

23andMe had devastating news about my health. I wish a person had delivered it

Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine

Racial disparities in Covid-19 are bad. They’re even worse in cancer

Elevated stress hormone levels could reawaken dormant cancer cells, study finds

Trump’s ‘most favored nations’ experiment undermines care for millions covered by Medicare

New cancer patients — especially Black people — are more susceptible to severe Covid-19 infections

Cancer is ‘natural.’ The best treatments for it aren’t

All Coverage

Triplet Therapeutics and three other startups got venture funding a year ago. Where are they now?

The biotech scorecard for the first quarter: 17 stock-moving events to watch

Agios sells cancer business to French drug maker for up to $2 billion, will now focus on inherited diseases

STAT’s most memorable photos of 2020

Covid-19 surge could lead to another drop in patient visits, doctors fear — and more missed pediatric cancers

‘Why would we ever go back?’: Covid-driven shift to remote cancer clinical trials will likely outlast the pandemic

With new data and a storied history, Eli Lilly’s blood cancer pill is looking stronger

Legend Biotech believes it is not a target of Chinese investigation, CEO says

‘How are we going to get on that plane?’: The transatlantic race to deliver CAR-T cancer therapy during the pandemic

Study offers new clues for treating brain cancer in children

As a kid, his factory work paid for his dad’s cancer care. As an oncologist, his research offers more than survival

The National Cancer Institute needs to publish information about chemical exposure and cancer risk

Cancer vaccine cocktail boosts immune response after melanoma surgery, research shows

A nudge helps doctors bring up end-of-life issues with their dying cancer patients

Cancer clinical trial enrollment has plummeted. Will patients come back amid Covid-19?

I was a ‘nonadherent’ patient. That’s made me a more empathetic doctor

After a breast cancer diagnosis, many Black women face barriers that delay their care

Training the innate immune system to thwart cancer could open door to a new therapy

Google and the Mayo Clinic to use AI to better target radiation therapy

Colorectal cancer screening should start five years earlier — at 45 — expert panel says

Exact Sciences acquires liquid biopsy company Thrive for $2.15 billion

Mirati study results set new response bar for KRAS-blocking lung cancer drugs

FDA pushes drug companies to include younger people in breast cancer drug trials

3 ways to counter Covid-19’s threat to community-based cancer care

CRISPR Therapeutics’ CAR-T treatment shows encouraging results, but one death is tied to therapy